Drugs Made In America Acquisition DMAA
NASDAQ DMAA
$10.75 +0.02 (+0.23%)
As of: Aug 21, 2026 · 2:31 PM EDT

Drugs Made In America Acquisition (DMAA) Total Non-Current Liabilities (2025)

Drugs Made In America Acquisition's (DMAA) quarterly Total Non-Current Liabilities came in at $6.9 million in Q4 2025.

Drugs Made In America Acquisition (DMAA) Total Non-Current Liabilities (2025) Analysis & Trends

Drugs Made In America Acquisition (DMAA) has 1 years of Total Non-Current Liabilities data on file, last reported at $6.9 million in Q4 2025.

  • Quarterly Total Non-Current Liabilities changed N/A year-over-year to $6.9 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $6.9 million (changed N/A YoY) and the FY2025 annual result came in at $6.9 million, changed N/A from the prior year.
  • Total Non-Current Liabilities held at $6.9 million in Q4 2025.
  • In the past five years, Total Non-Current Liabilities ranged from a high of $6.9 million in Q4 2025 to a low of $6.9 million in Q4 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Total Non-Current Liabilities (Qtr)
1 Oxley Bridge Acquisition 585.76 Mn 585.76 Mn - -
2 Launch Two Acquisition 557.86 Mn 557.86 Mn - 11.23 Mn
3 Drugs Made In America Acquisition 507.00 Mn 507.00 Mn - 17.50 Mn
4 Cantor Equity Partners IV 468.00 Mn 468.00 Mn - -
5 GP-Act III Acquisition 401.06 Mn 401.06 Mn - -
6 Aldel Financial 397.49 Mn 397.49 Mn - -
7 Republic Digital Acquisition 389.25 Mn 388.51 Mn - -
8 Gores Holdings X 385.06 Mn 384.87 Mn - 25.21 Mn
9 Agriculture & Natural Solutions Acquisition 377.29 Mn 377.04 Mn - 34.24 Mn
10 Drugs Made In America Acquisition 215.82 Mn 215.82 Mn - 6.19 Mn

Historic Data

Download Data
DateValue
Dec 31, 2025 6.90 Mn